Showing results (91-100 of 323) with videos related to
Sort By:
Pageof 33
The Lancet. Respiratory Medicine|December 20, 2016
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysisEmily A Kendall, Anthony T Fojo, David W DowdyThe Journal of Clinical Investigation|February 23, 2000
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugsM V Blagosklonny, R Robey, S Bates, et al.Cancer Treatment Reports|November 1, 1979
The delta and epsilon errors in the assessment of cancer clinical trialsM J Staquet, M Rozencweig, D D Von Hoff, et al.Cancer|February 1, 1981
Clinical trials with the hexitol derivatives in the U.SD F Chiuten, M Rozencweig, D D Von Hoff, et al.Cancer|July 1, 1977
VM 26 and VP 16-213: a comparative analysisM Rozencweig, D D Von Hoff, J E Henney, et al.Archiv Fur Geschwulstforschung|January 1, 1978
Current trends and prospects in surgical adjuvant trialsM Rozencweig, D D von Hoff, A C Louie, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 9, 1998
[Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines]Y Matsumoto, H Takano, S Nagao, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs FundA Aggarwal, T Fojo, C Chamberlain, et al.Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1980
N-(Phosphonacetyl)-L-aspartate (PALA): current statusM Rozencweig, R Abele, M Piccart, et al.Cancer Treatment Reports|September 1, 1987
Phase II trial of oral methotrexate and dipyridamole in colorectal carcinomaS Wadler, M Subar, M D Green, et al.Pageof 33